Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has applied for quotation on the ASX of 3,050,000 ordinary fully paid shares, issued on March 25, 2026 under an employee incentive scheme. The new securities, which are to be quoted despite any transfer restrictions, modestly increase the company’s free float and reflect the ongoing use of equity-based remuneration to align staff incentives with shareholder interests.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company listed on the ASX under the code MSB. The company focuses on developing and commercializing cellular medicines, with its securities actively traded on the Australian market as ordinary fully paid shares.
Average Trading Volume: 4,151,861
Technical Sentiment Signal: Sell
Current Market Cap: A$2.8B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.